GSK's ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms

The future of ViiV Healthcare's HIV business is injectable.

By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around £2 billion ($2.65 billion) in sales. And by 2031, it estimates that 90% of its business will be in that same long-acting market, executives said Monday on a call with investors.